Target Validation for Medicinal Chemists

Author:

Thomas Matthew1,Ewart Lorna2

Affiliation:

1. Boehringer Ingelheim Pharma GmbH & Co KG, Immunology and Respiratory Diseases Research Biberach Birkendorfer Strasse 65 88397 Biberach an der Riss Germany matthew_james.thomas@boehringer-ingelheim.com

2. Emulate Inc. 27 Drydock Avenue Boston MA 02210 USA

Abstract

Here we explore the essential elements of novel target identification and validation in the modern era of drug discovery. We discuss the utility of in vitro and in vivo technologies in the search and deconvolution of first-in-class targets, the opportunities each can provide when used effectively, and the challenges each represent. We consider the steps which bridge validation of a target and the initiation of drug discovery. We also explore the risks carried into the drug discovery process and how more advanced chemical matter can continue to build the validation package. Each section is supported by real-world examples in which such technologies have enabled novel target validation. We also provide a case study to illustrate target validation concepts throughout the life of a drug discovery project.

Publisher

The Royal Society of Chemistry

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3